Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi‑mode preemptive analgesia in elderly hip fracture
ChiCTR2500096043Phase 4Not yet recruiting
- Sponsor
- Yangpu District Central Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine and meloxicam in hip fracture, post-operative cognitive decline (POCD) and postoperative pain (3 arms), sponsored by Yangpu District Central Hospital. Primary endpoint: Incidence of postoperative cognitive dysfunction. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
bupivacainemeloxicam
03
Conditions
hip fracturepost-operative cognitive decline (POCD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2500096043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096043.